Evidence map›Paper›PMID 31863291›Full record

ArticleHuman cell2020

Patterns of immune infiltration in lung adenocarcinoma revealed a prognosis-associated microRNA-mast cells network.

Chunlin Wang, Xi Tang, Jiaojian Wang, Yanhua Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chunlin WangDepartment of Medical Oncology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, 434000, People's Republic of China.
Xi TangDepartment of Medical Oncology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, 434000, People's Republic of China.
Jiaojian WangDepartment of Medical Oncology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, 434000, People's Republic of China.
Yanhua XuDepartment of Medical Oncology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, 434000, People's Republic of China. zlkxyh@163.com.
First People's Hospital of Jingzhou · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune infiltration of tumor microenvironment is an important determinant for immune response and outcomes. To investigate the diversity and clinical relevance of immune infiltration in lung adenocarcinoma (LUAD), we performed a comprehensive analysis using the bulk tumor transcriptomes. The prognosis significance for immune infiltration was systematically evaluated and sufficient immune infiltration was associated with better outcomes. Resting mast cells emerged as the most strongly associated with better overall survival (OS) and disease-free survival (DFS), whereas the activated mast cells were correlated with adverse survival. Immune infiltration-based classification exhibited clinical relevance and provided a close link between cancer cell-intrinsic genetic events and immune landscape. The immune infiltration-miRNA functional network analysis showed that the resting mast cell-associated miRNAs are mainly involved in the enrichment of development, mRNA metabolic process, myeloid cell differentiation, Wnt, calcium modulating, interferon, p53 pathways. Additionally, we found one promoter (miR-30a) and one suppressor (miR-550a) of resting mast cells. Coupling the detailed analyses of the cellular immune infiltration and the implicated modulation role of miRNAs provides novel type of candidates for LUAD immunotherapy.

Indexed as

AdenocarcinomaHumansImmunotherapyLung NeoplasmsMast CellsMicroRNAsMolecular Targeted TherapyPrognosisMicroRNAsClassificationImmune infiltrationLung adenocarcinomaMast cellsPrognosis

Identifiers

PMID31863291
OpenAlexW2995541556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.